DailyIQ
|
Sector:HealthcareAll sectors
Last updated 6 minutes ago

RXRX·Recursion Pharmaceuticals Inc.

$.
-. (-.%)
After Hours
High
$3.80
Open
$3.80
Market Cap
1.89B
52W High
$7.18
Low
$3.44
P. Close
$3.56
P/E
-
52W Low
$2.77
Fwd P/E
-3.78
DailyIQ Est.
$7.58
Technical Score (1D)
64
BUY
News Sentiment
43
BEARISH
Recent earnings guidance shows a negative EPS of –$0.25 and a 37.64 % year‑over‑year revenue decline, indicating a sharp drop in profitability that will likely translate into a net loss of $0.99 per share for the full year. This negative outlook may prompt analysts to revise estimates and could lead to a reassessment of the company’s valuation over the next trading week. Meanwhile, the recent addition to multiple Russell indices has broadened the investor base and increased institutional exposure, which may offset some of the negative earnings impact in the short term. However, the high cash burn and over 90 % decline in shareholder returns over five years remain a concern, suggesting that the market may still view the stock as overvalued. The next key catalyst will be the clinical data from the REC‑4881 program, which could either validate the AI‑driven discovery platform or further dampen expectations. Traders should watch the earnings release for any revisions to the loss estimate and for guidance on cash burn and future funding needs. Additionally, monitoring the REC‑4881 data release and any regulatory updates will be crucial to gauge whether the pipeline can justify the current valuation. Finally, keep an eye on analyst revisions and short interest levels, as they will influence the stock’s volatility over the next 1–10 trading days.
Earnings Summary
Recursion Pharmaceuticals (RXRX) is a clinical‑stage biotechnology company that applies machine‑learning‑driven platforms to accelerate drug discovery, targeting conditions such as cerebral cavernous malformation, neurofibromatosis type 2, and Clostridioides difficile infection, and collaborating with major pharma partners. In the last two quarters, the company posted a loss of $0.21 EPS in Q4 2025, a turnaround from the negative earnings in earlier periods, and a loss of $0.22 EPS in Q1 2026, slightly better than the $0.25714 estimate; revenue surged to $35.54 million in Q4 2025 from $19.22 million in Q2 2025, but fell sharply to $6.47 million in Q1 2026, reflecting volatile top‑line performance; the firm has beaten analyst expectations in five of the last six quarters, with EPS exceeding guidance in Q4 2025 and Q1 2026, while earlier quarters saw misses. Historically, RXRX’s earnings trajectory has moved from consistent negative EPS in 2024 to a positive EPS in 2025, and revenue has shown large swings, with a 37.64 % YoY decline forecast for 2026, underscoring the company’s high cash burn and reliance on pipeline progress; the pattern of EPS beats amid revenue volatility highlights the importance of clinical milestones. Recent news highlights the firm’s addition to the Russell 2000 Value index, which may broaden its institutional base, and a price‑target lift to $125 by Evercore ISI, reflecting optimism about future revenue growth; analysts also caution that the company’s valuation remains high relative to its cash burn, and that upcoming REC‑4881 trial data could be a key catalyst. Investors should watch for the Q2 2026 earnings release for guidance on revenue, margin, and the status of the REC‑4881 program, as well as any updates on cost control or new clinical data that could influence the company’s risk profile.

EPS

EstBeatMiss
$-0.56$-0.46$-0.36$-0.26$-0.16Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$-0.23 - -
Q1'26$-0.26$-0.22+14.4%
Q4'25$-0.32$-0.21+33.3%
Q3'25$-0.38$-0.36+5.7%
Q2'25$-0.35$-0.41-16.0%
Q1'25$-0.52$-0.50+3.1%

Revenue

EstBeatMiss
$620,250$10M$20M$30M$40MQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$13M - -
Q1'26$16M$6M-59.0%
Q4'25$25M$36M+44.7%
Q3'25 - $5M -
Q2'25 - $19M -
Q1'25 - $15M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

RXRX Stock Snapshot

RXRX is currently trading at $3.56, giving Recursion Pharmaceuticals Inc. a market cap of 1.89B. Today's range spans $3.44–$3.80, with shares opening at $3.80 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 64/100 (HOLD) with a news sentiment reading of 43/100.

Over the past year RXRX has traded between $2.77 and $7.18 - the current price is +28.5% off the 52-week low and -50.4% from the high. 16 analysts cover the stock with a Buy consensus and a mean 12-month target of $7.25 (range $4.00–$10.00), implying upside of +103.7%.

Recursion Pharmaceuticals Inc. (RXRX) is a small-cap in Healthcare with 1.89B in market cap - and the current technical read of 64/100 (HOLD) alongside neutral sentiment (43/100) suggests limited near-term institutional demand. Price: $3.56 (near 52-week lows). At this capitalization, thin liquidity means that any change in sentiment can move the stock faster than the signal would suggest. Annual range: $2.77–$7.18.

The absence of strong institutional sponsorship makes RXRX's HOLD signal (64/100) more consequential than the same signal in a larger name — at 1.89B in Healthcare market cap, there are fewer natural buyers to absorb selling pressure, which means the $2.77–$7.18 range's lower bound becomes a sharper test of the thesis. Sentiment at 43/100 (neutral) and price at $3.56 (near 52-week lows) don't yet suggest stabilization is imminent.